The Boehringer Ingelheim Vetmedica, Inc. (BIVI) complete line of canine and feline vaccines is time-tested and proved safe and effective. They offer the latest vaccine technology with the most up-to-date protection against major dog and cat diseases. They are the most widely used vaccines in U.S. veterinary clinics today.
Founded in 1885, BIVI is a family-owned global company with 44,000 employees worldwide. The company has $1 billion in global animal health sales and ranks in the top five of all animal health companies. Boehringer-Ingelheim focuses on human and animal health, and markets products in 152 countries with more than $17 billion net sales.
BIVI operates four cutting-edge vaccine research centers in St. Joseph in Missouri and Fort Dodge, Ames and Sioux Center in Iowa. These centers are instrumental in innovative delivery technology.
BIVI works continuously to improve its world-class manufacturing process through technical expertise and state-of-the-art manufacturing practices. Biological production meets all global standards in manufacturing bacterial and viral vaccines, and produces more than 120 high-quality antigens placed in innovative products for dogs, cats, pigs, cattle and horses. Currently BIVI produces over 800 million doses of vaccine per year and estimates the number of doses will increase to a billion by 2015. All BIVI pet vaccines are made with PureFil™ Technology, exemplifying our commitment to quality and continuous improvement. BIVI is committed to finding new and innovative methods to provide pet owners products that are safe and effective.
The five pillars in the fountain represent the five continents where BIVI conducts business. (Above: Global Headquarters in Ingelheim, Germany.)